logo
logo

Impulse Dynamics Completes $101M Financing Round

May 12, 2022•about 3 years ago

Amount Raised

$101 Million

Description

Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today the completion of a $101 million financing round comprised of both equity and debt. Participants include new investors, Alger and Squarepoint Capital LLC; existing investors, Abiomed, Inc. and Kennedy Lewis Investment Management LLC; and private investors from the company’s Board of Directors, including the company’s CEO, Simos Kedikoglou, MD.

Company Information

Company

Impulse Dynamics

About

The AIM HIGHer trial is a 1,500-patient quadruple-blind, sham-controlled trial that the company has initiated to evaluate the potential of CCM therapy to improve performance and reduce cardiovascular morbidity and mortality in HF patients with left ventricular ejection fraction of 40 to 60 percent. The company pioneered CCM® therapy, which is delivered by the company’s Optimizer® Smart system, an FDA-approved treatment verified to improve the quality of life for heart failure patients. Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today the completion of a $101 million financing round comprised of both equity and debt.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People